【摘要】 目的探讨乳腺癌组织及外周血浆中E 钙粘素基因启动子的甲基化改变在乳腺癌诊断、复发中的作用。方法采用甲基化特异性PCR方法 (methylation specificPCR ,MSP) ,分别检测4 2例乳腺癌肿瘤组织、癌旁组织和外周血浆中游离DNAE 钙粘素基因的甲基化改变。结果 4 2例乳腺癌肿瘤组织中 ,E 钙粘素基因甲基化改变阳性率为 5 2 4 % (2 2 / 4 2 ) ,相应外周血浆中游离DNAE 钙粘素基因甲基化检出率为 33 3% (14 / 4 2 ) ,血浆中甲基化改变与肿瘤组织甲基化状况显著相关(P <0 0 0 1) ,肿瘤组织及血浆中E 钙粘素甲基化改变与乳腺癌病理特征无相关性。肿瘤组织无甲基化患者及良性疾病患者血浆中未发现E 钙粘素甲基化畸变。结论乳腺癌血浆中游离DNAE钙粘素甲基化改变检测在其早期诊断 ,评估疗效 ,监控复发及普查中应用具有一定的可行性。更多还原

【Abstract】 Objective To evaluate the feasibility in early diagnosis, predicting therapeutic effect, recurrence monitoring by examining promoter hypermethylation for cancer-associated genes E-cadherin in cancer tissue and peripheral blood of breast cancer patients. Methods The tumor tissue, paracancer- tissue and the paired plasma were examined for aberrant methylation of E-cadherin gene by methylation-specific PCR in 42 cases of breast cancer and 10 cases of breast benign diseases. Results The incidence of promoter hypermethylation of E-cadherin in tumor tissues was 52.4% and the paired plasma were 33.3%. E-cadherin hypermethylation in plasma samples and tumor samples significantly correlated with each other ( P< 0.001). There were no correlations for the aberrant methylation of cancer tissues and plasma with the clinicopathological parameters of patients. None of the aberrant methylation was found in paracancer normal tissues and control group plasma.Conclusion Our findings suggest that aberrant promoter methylation in the plasma can be detected in a substantial proportion of breast cancer patients,and it is useful in early diagnosis ,evaluating therapeutic effect, monitoring recurrence and mass screening.更多还原